Biopharma body relieved as SVB UK rescued

Today's Big News

Mar 13, 2023

Biden says America’s 'banking system is safe' after regulators back up all SVB deposits 


UK biopharma body praises bank for keeping doors open at life science startups by rescuing SVB UK


UPDATE: SVB failure triggers shock waves across biotech industry


GSK's $100M ADC bet in doubt after fatality in first trial of Mersana's cancer therapy


Heart tissue on a chip is headed back up to the International Space Station  

 

Featured

Biden says America’s 'banking system is safe' after regulators back up all SVB deposits

President Joe Biden looked to assure Americans that the banking system was safe after U.S. regulators announced they'd backup all depositors of Silicon Valley Bank. The move comes days after a $42 billion bank run tanked the once-heralded startup and biotech financier.
 

Top Stories

UK biopharma body praises bank for keeping doors open at life science startups by rescuing SVB UK

The U.K.'s BioIndustry Association has praised the government for securing a buyer for the U.K. subsidiary of the failed Silicon Valley Bank.

UPDATE: SVB failure triggers shock waves across biotech industry

Silicon Valley Bank’s capital raise of $2 billion has sent shock waves across the biotech industry and spurred a panic among some top venture capital firms that are urging their companies to withdraw deposits.

Raw materials matter in mRNA vaccine and therapeutic development

In the development of mRNA vaccines and therapeutics, identifying a raw materials supplier who can partner with you from preclinical to commercial supply is a key to success.

GSK's $100M ADC bet in doubt after fatality in first trial of Mersana's cancer therapy

An antibody-drug conjugate that GSK paid $100 million to license from Mersana Therapeutics has been slapped with a clinical hold after a patient died in the therapy’s first trial.

Heart tissue on a chip is headed back up to the International Space Station

Projects by teams from Stanford University and Johns Hopkins University will be part of the payload March 14 on SpaceX CRX-27, a resupply mission to the International Space Station. The researchers hope to leverage aging effects of microgravity on heart muscle cells to ultimately help identify new treatments for cardiovascular disease.

Sanofi throws down $2.9B to acquire diabetes partner Provention Bio

After Sanofi lost the bidding war for Horizon Therapeutics in December, the question wasn’t so much if the French pharma would pursue another buyout, but when.

With $43B buyout, Pfizer sees cancer specialist Seagen as a 'goose' laying 'golden eggs'

Scoring two of the three largest M&A deals in biopharma last year was just an appetizer for Pfizer. On Monday, the industry giant sat down to the main course, gobbling up Seattle cancer specialist Seagen for $43 billion. It is the largest acquisition in biopharma since June of 2019, when AbbVie acquired Allergan for $63 billion.

A 'magic whistle': Hands-free version of COPD breath tech improves airflow, study finds

A study published in the journal Respiratory Care this month found that University of Cincinnati startup PEP Buddy’s eponymous device significantly improved COPD patients’ breathlessness caused by physical activity.

Acadia's Daybue wins FDA nod as first treatment for Rett syndrome

Doctors and scientists have been studying Rett syndrome for decades, but up until now, there have been no approved treatments. Enter Acadia's Daybue.

Political headwinds grow against CMMI accelerated approval drug price model

CMMI is taking political heat from congressional Republicans over a proposed payment model that seeks to lower Medicare payments to drugs granted accelerated approval by the FDA.

The top 10 drugs losing US exclusivity in 2023

The Fierce Pharma team didn't want AbbVie's Humira to have the entire patent-cliff spotlight this year, so we're presenting this special report on the top U.S. losses of exclusivity in 2023. Besides Humira, drugs from J&J, AstraZeneca and more make the list.
 
Fierce podcasts

Don't miss an episode

'The Top Line': Why pharma needs to ramp up its use of AI and machine learning, plus this week's headlines

This week on "The Top Line," we take on AI and machine learning in the pharma and healthcare universe. The expectation is that these tools will speed up innovation and open up new markets, helping the sector stay ahead of the curve. Plus, this week's headlines.
 

Resources

Whitepaper

Plan for scalable process liquid and buffer preparation

Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation.

Executive Summary

Optimizing drug discovery in a fast-moving market

Read about the latest survey results from over 200 biopharma executives and the changing approaches to building biologic drug development pipelines.
Whitepaper

Answering your specific questions about mRNA/saRNA manufacturing

Have you had your questions about mRNA/saRNA manufacturing unanswered during a webinar; have no fear, we have you covered here.
Whitepaper

Proven Pharmaceutical Go-To-Market Model

Download Herspiegel Consulting’s Go-To-Market Model, based on 100+ launches, to learn the critical components, and timelines for commercial success.

Research

Strategizing for Clinical Trial Diversity

Like many top 10 and global pharma companies, an H1 client needed to diversify both its patient outreach and site investigator profiles for upcoming trials.
Whitepaper

The Power of Small & Safety: Nanoplasmid™️ Vector Platform

Discover the Power of Small with NanoplasmidTM – the next-generation plasmid for manufacturing today’s cell and gene therapies.

Whitepaper

Leveraging Archetypes for Effective Launch Strategy

Learn more about critical success factors for your next launch based on the experience of 100+ pharma product launches.
Whitepaper

Intranasal Drug Product Development: Formulation to Manufacturing

What are key considerations for intranasal delivery in the treatment of acute and chronic conditions?
Research

Step-wise strategy to address process characterization and late phase development

Learn more on Catalent’s step-wise approach for the definition and execution of Process Characterization for the production of a monoclonal antibody for late phase process characterization and development.

Whitepaper

Running Decentralized Trials at Scale

Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment.
Whitepaper

Key Clinical Supply Issues Sponsors Should Consider with their CRO

As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs.

Whitepaper

Specialized Expertise for Management of Clinical Supply Budgets

For sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management.
Whitepaper

Clinical Supply Solutions for the Asia-Pacific Region

Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region.
Whitepaper

Designing an Optimal APAC Clinical Supply Chain

Discover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific.
Whitepaper

Roles and Responsibilities of Specialized Clinical Supply Experts

How can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis.
Research

A Strategy to Standardize Process Characterization & Late Phase Development

Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments.

Whitepaper

Supply Services to Support Clinical Trials in Japan & Beyond

Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world.
Whitepaper

Questions You Need to Ask Your CRO About Clinical Supply

Planning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial.
Case Study

A Strategy to Standardize Process Characterization & Late Phase Development

Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments.

 

Industry Events

 

Upcoming Fierce Events

14-15
Mar
San Francisco, CA
20-22
Mar
West Palm Beach, FL
3-4
Apr
San Diego, CA
1-3
May
May 1-3, 2023 | Jersey City, NJ
23
May
Free Virtual Event

View all events